PL2488190T3 - Zmniejszanie ryzyka patologicznych skutków urazowego uszkodzenia mózgu - Google Patents

Zmniejszanie ryzyka patologicznych skutków urazowego uszkodzenia mózgu

Info

Publication number
PL2488190T3
PL2488190T3 PL10824055T PL10824055T PL2488190T3 PL 2488190 T3 PL2488190 T3 PL 2488190T3 PL 10824055 T PL10824055 T PL 10824055T PL 10824055 T PL10824055 T PL 10824055T PL 2488190 T3 PL2488190 T3 PL 2488190T3
Authority
PL
Poland
Prior art keywords
risk
reducing
brain injury
traumatic brain
pathological effects
Prior art date
Application number
PL10824055T
Other languages
English (en)
Polish (pl)
Inventor
Kevin Hadley
Terence. Fealey
Julian E. Bailes
Original Assignee
Dsm Ip Assets B.V.
West Virginia University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dsm Ip Assets B.V., West Virginia University filed Critical Dsm Ip Assets B.V.
Publication of PL2488190T3 publication Critical patent/PL2488190T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
PL10824055T 2009-10-13 2010-10-13 Zmniejszanie ryzyka patologicznych skutków urazowego uszkodzenia mózgu PL2488190T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25123009P 2009-10-13 2009-10-13
PCT/US2010/052564 WO2011047095A1 (en) 2009-10-13 2010-10-13 Reducing the risk of pathological effects of traumatic brain injury
EP10824055.7A EP2488190B1 (en) 2009-10-13 2010-10-13 Reducing the risk of pathological effects of traumatic brain injury

Publications (1)

Publication Number Publication Date
PL2488190T3 true PL2488190T3 (pl) 2018-02-28

Family

ID=43876523

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10824055T PL2488190T3 (pl) 2009-10-13 2010-10-13 Zmniejszanie ryzyka patologicznych skutków urazowego uszkodzenia mózgu

Country Status (8)

Country Link
US (2) US20110257267A1 (https=)
EP (1) EP2488190B1 (https=)
JP (3) JP2013507454A (https=)
AU (1) AU2010306870B2 (https=)
CA (1) CA2777367A1 (https=)
ES (1) ES2643628T3 (https=)
PL (1) PL2488190T3 (https=)
WO (1) WO2011047095A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110257267A1 (en) 2009-10-13 2011-10-20 Kevin Hadley Reducing the Risk of Pathological Effects of Traumatic Brain Injury
WO2012125020A1 (en) * 2011-03-14 2012-09-20 N.V. Nutricia Method for treating neurotrauma
US8792974B2 (en) 2012-01-18 2014-07-29 Brainscope Company, Inc. Method and device for multimodal neurological evaluation
US9269046B2 (en) 2012-01-18 2016-02-23 Brainscope Company, Inc. Method and device for multimodal neurological evaluation
US20190374502A1 (en) * 2017-02-09 2019-12-12 Bodhi Research & Development Inc. Cannabinoid-Containing Fatty Acid Formulations for Treating Disorders of the Nervous System
JP2020531589A (ja) * 2017-08-25 2020-11-05 ストラクト・ニュートリション・エルエルシー 頭部外傷後の神経損傷を予防、軽減、及び治療するための組成及び方法
KR101946362B1 (ko) 2017-10-27 2019-02-11 파이코일바이오텍코리아(주) 뇌 염증성 질환 예방, 개선 또는 치료용 조성물
CN111406110B (zh) * 2017-11-17 2023-08-08 广西小藻农业科技有限公司 藻类多不饱和脂肪酸的制备
AU2019371162B2 (en) 2018-11-02 2025-08-28 MARA Renewables Corporation Algal oil with improved nutritional value
WO2020254675A1 (en) 2019-06-20 2020-12-24 Aker Biomarine Antarctic As Parenteral lysophosphatidylcholine formulations such as lpc-dha, lpc-epa and their use in therapy
NL2023407B1 (en) 2019-06-28 2021-02-01 Aker Biomarine Antarctic As Parenteral lysophosphatidylcholine formulations
US20230398088A1 (en) * 2020-10-30 2023-12-14 The Trustees Of The University Of Pennsylvania Lipid Prophylactic Brain Injury Treatment
FR3132430B1 (fr) * 2022-02-09 2025-04-25 Polaris Composition comprenant un melange de dha et/ou d’epa et d’un phospholipide d’orgine vegetale

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US5506211A (en) * 1994-05-09 1996-04-09 The Uab Research Foundation Genistein for use in inhibiting osteroclasts
US6681403B2 (en) * 2000-03-13 2004-01-27 Robert M. Lyden Shin-guard, helmet, and articles of protective equipment including light cure material
US6469049B1 (en) * 2000-04-21 2002-10-22 The United States Of America As Represented By The Secretary Of The Army Method of treating, preventing or inhibiting central nervous system injuries and diseases
AU2002352726A1 (en) * 2001-11-15 2003-06-10 Galileo Laboratories, Inc. Formulations and methods for treatment or amelioration of inflammatory conditions
WO2005063296A2 (en) * 2003-12-23 2005-07-14 Pfizer Products Inc. Therapeutic combination for cognition enhancement and psychotic disorders
US20050164908A1 (en) 2004-01-23 2005-07-28 Ginsberg Myron D. Neuroprotective complex for treatment of cerebral ischemia and injury
US20060276373A1 (en) 2004-01-23 2006-12-07 Bazan Nicolas G Neuroprotective complex for treatment of cerebral ischemia and injury
US20060059605A1 (en) * 2004-09-22 2006-03-23 Xenith Athletics, Inc. Layered construction of protective headgear with one or more compressible layers of thermoplastic elastomer material
JP5697293B2 (ja) * 2005-06-30 2015-04-08 サントリーホールディングス株式会社 器質的脳障害に起因する高次脳機能の低下に対する改善作用を有する組成物
BRPI0613358A8 (pt) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
US20080038237A1 (en) * 2006-02-28 2008-02-14 Sapolsky Robert M Trojan horse immunotherapy
CN101049297B (zh) 2006-04-06 2010-11-24 北京百慧生化制药有限责任公司 一种高dha型-乙酯和epa-乙酯的脂肪酸乙酯及其制造方法和制剂
AU2008269989B2 (en) * 2007-06-29 2014-02-27 Dsm Ip Assets B.V. Production and purification of esters of polyunsaturated fatty acids
WO2009057994A1 (en) * 2007-11-02 2009-05-07 N.V. Nutricia Unit dosage for brain health
US20110257267A1 (en) 2009-10-13 2011-10-20 Kevin Hadley Reducing the Risk of Pathological Effects of Traumatic Brain Injury
CN109350408B (zh) * 2018-12-11 2024-06-14 陶国民 过床护理椅

Also Published As

Publication number Publication date
AU2010306870A1 (en) 2012-05-03
EP2488190B1 (en) 2017-09-20
WO2011047095A1 (en) 2011-04-21
ES2643628T3 (es) 2017-11-23
US20190046495A1 (en) 2019-02-14
EP2488190A4 (en) 2013-03-27
AU2010306870B2 (en) 2016-08-18
JP6516158B2 (ja) 2019-05-22
JP2016053065A (ja) 2016-04-14
CA2777367A1 (en) 2011-04-21
JP2018021067A (ja) 2018-02-08
EP2488190A1 (en) 2012-08-22
JP2013507454A (ja) 2013-03-04
JP6544747B2 (ja) 2019-07-17
AU2010306870A8 (en) 2012-06-28
US20110257267A1 (en) 2011-10-20
US11413263B2 (en) 2022-08-16

Similar Documents

Publication Publication Date Title
PL2488190T3 (pl) Zmniejszanie ryzyka patologicznych skutków urazowego uszkodzenia mózgu
HUE040281T2 (hu) Autoantitest markerek traumás agysérülés diagnózisára
IL225731A0 (en) Biomarkers for brain injury
GB0911580D0 (en) Use of one or more cannabinoids in the treatment of epilepsy
IL217901A0 (en) Treatment of bdnf-related disorders using laquninimod
IL253293A0 (en) Desferrioxamine complexes of metals for the treatment of diseases related to the immune system
GB0919568D0 (en) Skin stimulus
GB0915515D0 (en) Treatment of vasculoproliferative conditions
ZA201106294B (en) Treatment of dyskinesia related disorders
SG2014014724A (en) METHODS FOR THE TREATMENT OF IL-1ß RELATED CONDITIONS
IL213761A0 (en) Novel ortho-aminoamides for the treatment of cancer
GB0904287D0 (en) Compounds for the treatment of metabolic disorders
GB0904285D0 (en) Compounds for the treatment of metabolic disorders
EP2621498A4 (en) COMBINED TREATMENT OF DERMATOLOGICAL CONDITIONS
IL225896A0 (en) Treatment of mecp-2 related disorders
ZA201107445B (en) Compound for the treatment of metabolic disorders
IL214133A0 (en) Skin treatment
PL2477656T3 (pl) Leczenie stanów neurologicznych
ZA201204391B (en) Compounds for the treatment of neurologic disorders
GB0914839D0 (en) Treatment of oil
EP2531186A4 (en) TREATMENT OF HAIR DRESSES
ZA201005770B (en) The treatment of damaged skin
GB0814043D0 (en) The treatment of skin disorders
PT2456445E (pt) Agente para o tratamento de condições da pele
GB201003124D0 (en) Treatment of oxidative stress disorders